Navigation Links
Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery

Ultra-Fine Beam Shaping Device Optimized for Targeting Tumors and Other Abnormalities with High-Dose Stereotactic Radiotherapy and Radiosurgery

PALO ALTO, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Varian Medical Systems, Inc. (NYSE: VAR) has received FDA 510(k) clearance for a new high-definition multileaf collimator (MLC), an ultra-fine beam shaping device for radiosurgery.

The new HD120 MLC multileaf collimator enables clinicians to deliver extremely precise radiosurgical treatments, including intensity-modulated radiosurgery (IMRS), and will be included with the new Novalis Tx(R) radiosurgery system that Varian is teaming up with BrainLab to offer (see related press release entitled Varian Medical Systems and BrainLAB Join Forces to Introduce Novalis Tx(R)).

The Novalis Tx offers a non-invasive alternative to conventional surgery for a wide spectrum of conditions, including benign and malignant tumors, metastatic cancer, and neurological conditions like arteriovenous malformations, trigeminal neuralgia, and acoustic schwannoma.

"Successful irradiation of these types of abnormalities depends on doctors' ability to deliver a high dose of radiation with the precision of a surgical strike, sparing the surrounding tissues," said Calvin Huntzinger, MS, marketing and engineering manager for Varian's Surgical Sciences product line. "Varian's new HD120 MLC multileaf collimator doubles the resolution of our best MLC, so it is ideal for carrying out delicate intensity-modulated radiosurgeries near critical structures like the optic chiasm, brain stem, or spinal cord."

A multileaf collimator is a device with many computer-controlled mechanical "leaves" or "slats" that continually shape the treatment beam as the radiation is delivered from different angles around the patient. Prior to the new HD120 MLC multileaf collimator, Varian's finest MLC had a central group of beam-shaping leaves that were each 5 millimeters wide. The HD120 MLC has reduced the width of the central leaves to just 2.5 millimeters, increasing the beam-shaping precision by 100 percent.

The new collimator also offers improved dose delivery characteristics, including a steeper dose fall-off gradient, so that the amount of dose delivered decreases rapidly outside the targeted area, protecting healthy tissues more effectively than is possible with earlier beam shaping devices. The HD120 MLC was also designed for durability, so that it can be relied upon during continual use in a busy clinic.

"This new high-definition multileaf collimator builds on Varian's widely recognized accomplishments in advancing MLC technology, and underscores our commitment to meeting the unique needs of clinicians offering stereotactic radiosurgery and stereotactic body radiotherapy," Huntzinger said. Varian already offers the broadest range of beam-shaping products, including 52-, 80- and 120-leaf collimators for radiation oncology. Multileaf collimators are now included with nearly every order for Varian's linear accelerators.

"The multi-leaf collimator has revolutionized radiotherapy and it is now poised to do the same with radiosurgery," Huntzinger said. "We are committed to extending this life-saving technology to help more patients in a broader range of cases."


Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,400 people who are located at manufacturing sites in North America, China, and Europe and approximately 60 sales and support offices around the world. For more information, visit


Statements in this press release regarding future business, events, plans, objectives, expectations, estimates, and other similar matters, including, but not limited to, statements using the terms "offers," "can be," and "is poised" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the risks described in the company's Annual Report on Form 10-K and other reports filed from time to time by the Company with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company assumes no obligation to update or revise these forward-looking statements because of new information, future events, or otherwise.


Spencer Sias (650) 424-5782

Meryl Ginsberg (650) 424-6444

SOURCE Varian Medical Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Using XL1-Red Mutator Strain to Generate Esterase Variants
2. Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing
3. Detection of Apolipoprotein Gene Variants by DGGE Using the DCode System
4. Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives in the yeast Saccharomyces cerevisiae: Detection in vivo using the Varian Cary Eclipse
5. Monitoring fluorescence resonance energy transfer (FRET) between GFP fusions in lysates of the yeast Saccharomyces cerevisiae using the Varian Cary Eclipse
6. Minimizing Photobleaching of Blue Fluorescent Protein (BFP) using the Varian Cary Eclipse Fluorescence Spectrophotometer
7. Detection of Morphine and Morphine-Glucuronide in Saliva or Urine with a Rapid and Simple Method Without Derivatization on the Varian 500-MS
8. Detection of Alprazolam and Temazepam in a Bovine Plasma Matrix Using the Varian 500-MS Ion Trap Mass Spectrometer
9. Quantitation of Oxybutynin in Rabbit Plasma Using the Varian 1200L LC/MS/MS System
10. Femtogram Sensitivity of the Antipsychotic Drugs Raclopride and Ritanserin Using a Varian 1200L LC/MS/MS
11. Quantitation of a Dinitro Flavonoid (DNF) in Rat Plasma Using the Varian 1200L LC/MS/MS System
Post Your Comments:
(Date:11/30/2015)... BETHESDA, Md. , Nov. 30, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for solid ... to adding an additional independent director, and the Company ... investigation of allegations in a recent anonymous internet report ... on both initiatives. Linda Powers stated, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
Breaking Biology News(10 mins):